Listening in on the Microbubble Crowd: Advanced Acoustic Monitoring for Improved Control of Blood-Brain Barrier Opening with Focused Ultrasound
Overview
Affiliations
Non-invasive drug and gene delivery to the brain to treat central nervous system pathologies has long been inhibited by the blood-brain barrier. The activation of microbubbles with focused ultrasound has emerged as a promising non-invasive approach to circumvent this obstacle, by transiently disrupting the blood-brain barrier and permitting passage of systemically administered therapeutics into the tissue. Clinical trials are underway to evaluate the safety of this technique; however, concerns remain regarding the potential for the treatment to induce sterile inflammation or petechiae. In this issue of , Jones et al.[1] address these concerns through the development of an advanced three-dimensional imaging system for monitoring acoustic emissions from oscillating microbubbles. When subharmonic emissions are detected with this system, focused ultrasound pressure is reduced by 50% for the remainder of the treatment. This serves to transiently open the blood-brain barrier without generating adverse effects. While the ideal configuration of the transducer array for treatment and monitoring still presents an area for further optimization, the approach indicates that the acoustic signature of microbubble behavior within the skull can be used to ensure safe and effective blood-brain barrier opening using focused ultrasound.
The blood-brain barriers: novel nanocarriers for central nervous system diseases.
Liu J, Wang T, Dong J, Lu Y J Nanobiotechnology. 2025; 23(1):146.
PMID: 40011926 PMC: 11866817. DOI: 10.1186/s12951-025-03247-8.
Advancements and challenges in brain cancer therapeutics.
Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.
PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.
Functionalized Nanomaterials Capable of Crossing the Blood-Brain Barrier.
Zha S, Liu H, Li H, Li H, Wong K, All A ACS Nano. 2024; 18(3):1820-1845.
PMID: 38193927 PMC: 10811692. DOI: 10.1021/acsnano.3c10674.
MST1/2 in inflammation and immunity.
Li T, Wen Y, Lu Q, Hua S, Hou Y, Du X Cell Adh Migr. 2023; 17(1):1-15.
PMID: 37909712 PMC: 10761064. DOI: 10.1080/19336918.2023.2276616.
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment.
Li W, Xu X Front Pharmacol. 2023; 14:1211719.
PMID: 37456742 PMC: 10347406. DOI: 10.3389/fphar.2023.1211719.